|Calculated MW||24 kDa, monomer, non-glycosylated|
|Other Names||Interleukin-28A, IL-28A, IFN-Lambda 2, Interferon-Lambda 2, Cytokine ZCYTO20, IL28A, IFNL2, ZCYTO20.|
|Source||Human 293 cell expressed|
|Assay&Purity||SDS-PAGE; > 95%|
|Results||0.5 to 5 ng/ml|
|Application Notes||Reconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.|
|Storage||-80°C; Lyophilized in PBS.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IL-28A is distantly related to type I interferons and the IL-10 family. Expression of IL-28A is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha. IL-28A exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumor activity. They act similarly to IFNs, but are less effective generally and have activity in a more limited range of cell lines. IL-28A induces ELR (-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. It is able to generate tolerogenic DCs, an activity that could thwart IFN-beta functions. IL-28A produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection.
Sheppard P.,et al.Nat. Immunol. 4:63-68(2003).
Zhu H.,et al.Virol. J. 2:80-80(2005).
Kotenko S.V.,et al.Nat. Immunol. 4:69-77(2003).
Li M.C.,et al.Acta Pharmacol. Sin. 27:453-459(2006).
Donnelly R.P.,et al.J. Interferon Cytokine Res. 30:555-564(2010).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.